This inventor holds 1 USPTO granted patent. Top assignee: Idorsia Pharmaceuticals Ltd. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovative Contributions of Magdalena Birker
Introduction
Magdalena Birker is a notable inventor based in Allschwil, Switzerland. She has made significant strides in the field of pharmaceuticals, particularly in the treatment of fibrotic diseases. Her work exemplifies the intersection of innovation and healthcare, showcasing the potential of scientific advancements to improve patient outcomes.
Latest Patents
Magdalena Birker holds a patent for a groundbreaking invention titled "Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases." This patent involves compounds that act as antagonists of the LPA receptor, combined with therapeutically active ingredients such as pirfenidone and nintedanib. The invention aims to prevent and treat fibrotic diseases, highlighting the importance of her research in developing effective therapies.
Career Highlights
Birker's career is marked by her dedication to pharmaceutical innovation. She is currently associated with Idorsia Pharmaceuticals Ltd., where she continues to contribute to the development of novel treatments. Her expertise in the field has positioned her as a key player in advancing therapeutic options for patients suffering from fibrotic conditions.
Collaborations
Magdalena Birker collaborates with Cyrille Lescop, enhancing the research and development efforts at Idorsia Pharmaceuticals Ltd. Their partnership exemplifies the collaborative spirit essential for driving innovation in the pharmaceutical industry.
Conclusion
Magdalena Birker's contributions to the field of pharmaceuticals, particularly through her patent on LPA receptor antagonists, underscore her role as an influential inventor. Her work not only advances scientific knowledge but also holds the promise of improving treatment options for patients with fibrotic diseases.